文献速递前列腺癌

前列腺癌盆腔淋巴结清扫指征与并发症:现有列线图预测淋巴结侵犯的准确性

Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion.
PubMed 文献 · BJU Int · 2020-09-19

各模型AUC相似(0.76-0.81),但均存在校准偏差;ePLND相关并发症发生于8.9%患者。

要点

  • 现有列线图预测LNI的AUC相似,但均存在校准偏差。
  • 仅系统穿刺患者中,MSKCC和Briganti 2012列线图预测更优。
  • ePLND相关并发症发生率为8.9%。

核心结论

  • 现有列线图预测LNI性能相似且均有局限性,均存在校准偏差但决策曲线分析显示净获益。
  • 在仅接受系统穿刺的患者中,MSKCC和Briganti 2012列线图预测LNI更优。

研究设计与样本

  • 其中609例接受了多参数磁共振靶向穿刺。

主要发现

  • 1158例(9.6%)存在淋巴结侵犯,平均切除淋巴结17.7枚、阳性淋巴结3.2枚。
  • 各列线图AUC无显著差异:MSKCC 0.79、Briganti 2012 0.79、Partin 2016 0.78、Yale 0.80、Briganti 2017 0.81、Briganti 2019 0.76。
  • 旧版模型倾向低估LNI风险,Briganti 2017和2019列线图倾向高估LNI风险。
  • 决策曲线分析显示所有模型均有净获益,Partin 2016和Briganti 2019模型净获益较低。
  • ePLND相关并发症发生于1027例(8.9%),pN1患者中为12.6%。

关键数值与推荐

  • 各列线图AUC:MSKCC 0.79、Briganti 2012 0.79、Partin 2016 0.78、Yale 0.80、Briganti 2017 0.81、Briganti 2019 0.76。
  • ePLND相关并发症包括淋巴囊肿、淋巴水肿、出血、感染和脓毒症,总发生率8.9%。

临床怎么用

  • 选择列线图预测LNI时需注意校准偏差,旧版模型倾向低估风险,Briganti 2017/2019倾向高估。
  • 仅系统穿刺患者可优先考虑MSKCC或Briganti 2012列线图。
  • 使用推荐阈值决定ePLND时需权衡并发症风险(总体8.9%)。

局限性

  • 回顾性研究设计。
  • 仅609例接受靶向穿刺,可能影响列线图在靶向穿刺人群中的适用性。
  • 未报告列线图推荐阈值下的具体并发症风险数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To externally validate the currently available nomograms for predicting lymph node invasion (LNI) in patients with prostate cancer (PCa) and to assess the potential risk of complications of extended pelvic lymph node dissection (ePLND) when using the recommended threshold. METHODS: A total of 14 921 patients, who underwent radical prostatectomy with ePLND at eight European tertiary referral centres, were retrospectively identified. After exclusion of patients with incomplete biopsy or pathological data, 12 009 were included. Of these, 609 had undergone multiparametic magnetic resonance imaging-targeted biopsies. Among ePLND-related complications we included lymphocele, lymphoedema, haemorrhage, infection and sepsis. The performances of the Memorial Sloan Kettering Cancer Centre (MSKCC), Briganti 2012, Briganti 2017, Briganti 2019, Partin 2016 and Yale models were evaluated using receiver-operating characteristic curve analysis (area under the curve [AUC]), calibration plots, and decision-curve analysis. RESULTS: Overall, 1158 patients (9.6%) had LNI, with a mean of 17.7 and 3.2 resected and positive nodes, respectively. No significant differences in AUCs were observed between the MSKCC (0.79), Briganti 2012 (0.79), Partin 2016 (0.78), Yale (0.80), Briganti 2017 (0.81) and Briganti 2019 (0.76) models. A direct comparison of older models showed that better discrimination was achieved with the MSKCC and Briganti 2012 nomograms. A tendency for underestimation was seen for all the older models, whereas the Briganti 2017 and 2019 nomograms tended to overestimate LNI risk. Decision-curve analysis showed a net benefit for all models, with a lower net benefit for the Partin 2016 and Briganti 2019 models. ePLND-related complications were experienced by 1027 patients (8.9%), and 12.6% of patients with pN1 disease. CONCLUSIONS: The currently available nomograms have similar performances and limitations in the prediction of LNI. Miscalibration was present, however, for all nomograms showing a net benefit. In patients with only systematic biopsy, the MSKCC and Briganti 2012 nomograms were superior in the prediction of LNI.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Oderda M, Diamand R, Albisinni S, et al. Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion. BJU Int. 2020. PMID: 32869940. doi:10.1111/bju.15220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。